Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases

US11020473B2 · kind B2 · utility

Assignees

• INSTITUT PASTEUR · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• MINISTÈRE DES ARMÉES—Direction Centrale du Service de Sante des Armée · FR

Inventors

• Frédéric Tangy · Les Lilas, FR
• Anastassia KOMAROVA · Arcueil, FR
• Marie MURA · Arpajon, FR
• Chantal Combredet · Paris, FR

Key dates

• Filing date: Jun 23, 2017
• Grant date: Jun 1, 2021
• Expiry date: Jun 23, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.